These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 6457729

  • 1. Studies on ovarian and adrenal steroids at different phases of the menstrual cycle. III. Steroid and lutropin levels before and after the administration of a single contraceptive dose of depot-medroxyprogesterone acetate (DMPA).
    Aedo AR, Landgren BM, Diczfalusy E.
    Contraception; 1981 Aug; 24(2):117-35. PubMed ID: 6457729
    [Abstract] [Full Text] [Related]

  • 2. Studies on ovarian and adrenal studies at different phases of the menstrual cycle. IV. The effect of dexamethasone suppression and subsequent ACTH stimulation at different phases of the menstrual cycle and following the administration of 150 mg of depot-medroxy-progesterone acetate (DMPA).
    Aedo AR, Landgren BM, Diczfalusy E.
    Contraception; 1981 Nov; 24(5):543-58. PubMed ID: 6274585
    [Abstract] [Full Text] [Related]

  • 3. Studies on ovarian and adrenal steroids at different phases of the menstrual cycle: II. A comparative assessment of the circadian variation in steroid and lutropin levels during the follicular, periovulatory and luteal phases.
    Aedo AR, Landgren BM, Diczfalusy E.
    Contraception; 1981 Apr; 23(4):407-24. PubMed ID: 7273761
    [Abstract] [Full Text] [Related]

  • 4. Studies on ovarian and adrenal steroids at different phases of the menstrual cycle. 1. Dynamic changes during the periovulatory period.
    Aedo AR, Landgren BM, Diczfalusy E.
    Contraception; 1981 Feb; 23(2):107-24. PubMed ID: 7238039
    [Abstract] [Full Text] [Related]

  • 5. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study.
    Lan PT, Aedo AR, Landgren BM, Johannisson E, Diczfalusy E.
    Contraception; 1984 Jan; 29(1):1-18. PubMed ID: 6234145
    [Abstract] [Full Text] [Related]

  • 6. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 7. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
    Jeppsson S, Johansson ED, Ljungberg O, Sjöberg NO.
    Acta Obstet Gynecol Scand; 1977 Nov; 56(1):43-8. PubMed ID: 842303
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A, Faure N, Labrie F, Fazekas AT.
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [Abstract] [Full Text] [Related]

  • 9. Effect of depo-medroxyprogesterone acetate on serum progesterone levels when administered on various cycle days.
    Siriwongse T, Snidvongs W, Tantayaporn P, Leepipatpaiboon S.
    Contraception; 1982 Nov; 26(5):487-93. PubMed ID: 6218964
    [Abstract] [Full Text] [Related]

  • 10. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.
    Shumin X, Johannisson E, Landgren BM, Diczfalusy E.
    Contraception; 1983 Feb; 27(2):177-93. PubMed ID: 6851555
    [Abstract] [Full Text] [Related]

  • 11. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
    Soufir JC, Jouannet P, Marson J, Soumah A.
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
    [Abstract] [Full Text] [Related]

  • 12. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
    de Greef WJ, Dullaart J, Zeilmaker GH.
    J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
    [Abstract] [Full Text] [Related]

  • 13. Studies on the pattern of circulating steroids in the normal menstrual cycle. Circadian variation in theperi-ovulatory period.
    Aedo AR, Nuñez M, Landgren BM, Cekan SZ, Diczfalusy E.
    Acta Endocrinol (Copenh); 1977 Feb; 84(2):320-32. PubMed ID: 138325
    [Abstract] [Full Text] [Related]

  • 14. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
    Jeppsson S, Gershagen S, Johansson ED, Rannevik G.
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995
    [Abstract] [Full Text] [Related]

  • 15. Estrogenic activity in women receiving an injectable progestogen for contraception.
    Mishell DR, Kharma KM, Thorneycroft IH, Nakamura RM.
    Am J Obstet Gynecol; 1972 Jun 01; 113(3):372-6. PubMed ID: 4637029
    [Abstract] [Full Text] [Related]

  • 16. Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human.
    Kumari GI, Das RP, Madoiya KK, Jain AK, Roy S.
    Fertil Steril; 1977 Nov 01; 28(11):1168-74. PubMed ID: 562781
    [Abstract] [Full Text] [Related]

  • 17. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA, Faúndes A, Dunson TR, Ramos M, DeLucio M, Faúndes D, Bahamondes L.
    Fertil Steril; 1998 Nov 01; 70(5):817-20. PubMed ID: 9806559
    [Abstract] [Full Text] [Related]

  • 18. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones.
    Adlercreutz H, Pulkkinen MO, Hämäläinen EK, Korpela JT.
    J Steroid Biochem; 1984 Jan 01; 20(1):217-29. PubMed ID: 6231418
    [Abstract] [Full Text] [Related]

  • 19. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A, Faure N.
    J Clin Endocrinol Metab; 1986 Dec 01; 63(6):1379-85. PubMed ID: 2946711
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.